22911-39-3

Usage

Uses

Used in Pharmaceutical Industry:
4-(Nitrooxy)butan-1-ol is used as a vasodilator for the treatment of angina, heart failure, and high blood pressure. Its ability to relax and dilate blood vessels allows for increased blood flow to the heart, reducing the workload on the heart and alleviating chest pain.
Used in Emergency Medicine:
4-(Nitrooxy)butan-1-ol is used as an emergency medication to relieve acute episodes of chest pain and prevent potential heart attacks. Its rapid onset of action makes it an essential component in the management of acute coronary syndromes.
Used in Various Forms:
4-(Nitrooxy)butan-1-ol is available in different forms, including tablets, ointments, and sprays, to cater to various patient needs and preferences. It is typically administered sublingually or transdermally for quick absorption and immediate effect.
Used with Caution:
Due to its potent vasodilatory effects, 4-(Nitrooxy)butan-1-ol must be used cautiously and under medical supervision. Potential side effects include headaches, dizziness, and low blood pressure, which can be mitigated through proper dosage adjustments and monitoring.
Used with Extreme Care:
As a highly explosive compound, 4-(Nitrooxy)butan-1-ol requires careful handling and storage to prevent accidents and ensure safety. Strict safety protocols and guidelines must be followed during its production, transportation, and usage.

InChI:InChI=1/C4H9NO4/c6-3-1-2-4-9-5(7)8/h6H,1-4H2

Upstream product

• 110-63-4 Butane-1,4-diol 
• 907624-85-5 acetic acid 4-nitryloxybutyl ester 
• 1100273-14-0 4-nitrooxybutan-1-ol butyrate 
• 1141845-41-1 4-(nitrooxy)butyl 4-nitrobenzoate 
• 1141845-42-2 3-nitrobenzoic acid 4-nitryloxybutyl ester 

Downstream Products

• 1538580-29-8 (Z)-4-(nitrooxy)butyl 2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetate 
• 1415910-90-5 4-(nitrooxy)butyl N-((benzyloxy)carbonyl)-2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]-2-amino-acetate 
• 1415910-89-2 4-(nitrooxy)butyl N-((benzyloxy)carbonyl)-2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]-2-amino-acetate 
• 1415910-86-9 4-(nitrooxy)butyl N-(tert-butoxycarbonyl)-2-(1-(3-fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino-acetate 
• 1415910-85-8 4-(nitrooxy)butyl N-(tert-butoxycarbonyl)-2-(1-(4-fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino-acetate 
• 1346556-25-9 4-(nitrooxy)butyl N-[(4-methyl-5-thiazolyl)phenylmethyl]carbamate 
• 163133-43-5 naproxcinod 
• 1357362-70-9 2-formylphenyl (4-(nitrooxy) butyl) succinate 

Relevant academic research and scientific papers

PROCESS FOR THE MANUFACTURE OF OMEGA NITROOXY-1-ALKANOLS

The invention relates to a process for the preparation of ω-nitroxyC3-10 alkane-1-ols comprising the nitration of an α,ω-C 3-10 alkanediol with a nitration agent, optionally in the presence of a nitrite trapping agent, characterized in that the nitration agent is a mixture consisting of 50 to 75 wt.-% of nitric acid in water wherein the nitric acid is used in an amount selected in the range from 0.5 to 5 mol equivalents based on the α,ω--C3-10alkanediols, and wherein the nitration is carried out at a temperature selected in the range from 65 - 100°C.

Design, synthesis and biological activity evaluation of NO donor-containing ferrocene-pyrazole derivative

The invention discloses an NO donor-containing ferrocene-pyrazole derivative and a preparation method thereof. A structure of the NO donor-containing ferrocene-pyrazole derivative is shown by the following formula, wherein R is selected from the following groups.

Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy

A series of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy were designed, synthesized and biologically evaluated. Among them, compound 7l displayed the most potent inhibitory against COX-2 (IC50 = 0.82 μM) and antiproliferative activities against Hela cells (IC50 = 0.34 μM) compared with Celecoxib (IC50 = 0.38 and 7.91 μM). The further mechanistic studies revealed that 7l could induce apoptosis of Hela cells by mitochondrial depolarization and the antiproliferative activities of 7l were positively correlated with the levels of intracellular NO release in Hela cells. Most notably, 7l could dramatically suppress tumor growth in Hela cells xenografted mouse model. In summary, compound 7l may be promising candidates for cancer therapy.

Synthesis and biological evaluation of nitric oxide-donating analogues of sulindac for prostate cancer treatment

A series of analogues of the non-steroidal anti-inflammatory drug (NSAID) sulindac 1 were synthesised tethered to nitric oxide (NO) donating functional groups. Sulindac shows antiproliterative effects against immortal PC3 cell lines. It was previously demonstrated that the effect can be enhanced when tethered to NO releasing groups such as nitrate esters, furoxans and sydnonimines. To explore this approach further, a total of fifty-six sulindac-NO analogues were prepared and they were evaluated as NO-releasing cytotoxic agents against prostate cancer (PCa) cell lines. Compounds 1k and 1n exhibited significant cytotoxic with IC50 values of 6.1 ± 4.1 and 12.1 ± 3.2 μM, respectively, coupled with observed nitric oxide release.

QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE

The present invention relates to nitric oxide donor compounds having a quinone based structure of formula (I), wherein R1 to R6, n, m and p are as defined in claim 1, compositions thereof and said compounds for use in the treatment and/or prophylaxis of glaucoma and ocular hypertension.

QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS

The present invention relates to nitric oxide donor compounds having a quinone based structure of formula (I), wherein R1 to R6, m, n and p are as defined in claim 1, to processes for their preparation and to their use in the treatment of pathological conditions where a deficit of NO plays an important role in their pathogenesis, such as pulmonary arterial hypertension, Sickle cell disease, systemic sclerosis and scleroderma, muscular dystrophies, Duchenne's muscular dystrophy and Becker's muscular dystrophy, vascular dysfunctions.

QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS

The present invention relates to nitric oxide donor compounds having a quinone based structure, to processes for their preparation and to their use in the treatment of pathological conditions where a deficit of NO plays an important role in their pathogen

NITRIC OXIDE DONOR NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, R7, R8, Z, X, b, and c are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are nitric oxide donors and have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

ANHYDRIDE DERIVATIVES OF 2-(S)-(6-METHOXY-2-NAPHTYL)-PROPANOIC ACID, PREPARATION METHOD AND USE THEREOF

The present invention provides a novel anhydride derivative of 2-(S)-(6-methoxy-2-naphtyl)-propanoic acid for preparing nitrooxyalkyl esters of 2-(S)-(6-methoxy-2-naphtyl)-propanoic acid with high purity to meet requirements of the industry.

Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzyme

The development of a novel class of pharmacodynamic hybrids that inhibits COX-2 isoform is reported. These molecules display enhanced nitric oxide releasing properties due to the presence of an ionisable moiety. The in vivo analgesic/anti-inflammatory activity was maintained in relation to the parent compounds.